In the throes of the worldwide Covid-19 crisis, the antiparasitic drug, ivermectin, became a fiercely contested subject among health professionals and the public. Preliminary lab studies hinting at its antiviral properties against SARS-CoV-2 led to an uptick in curiosity. These results triggered numerous international clinical trials to gauge its efficiency and safety in treating Covid-19.